Company intelligence / Profile preview

JuntuCell

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

JuntuCell is a China-based biotechnology company specializing in the development of next-generation cell therapies for oncology. The company focuses on overcoming the limitations of current CAR-T treatments by developing universal, off-the-shelf cell products and therapies targeting solid tumors. Their research encompasses CAR-T, TCR-T, and NK cell-based modalities, utilizing advanced gene editing and cell engineering technologies. JuntuCell aims to improve the accessibility and efficacy of immunotherapy for patients with hematological malignancies and difficult-to-treat solid cancers.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T cell therapyNK cell therapyT cell receptor engineered T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on JuntuCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JuntuCell.

Explore the full profile